Research programme: gp41 fusion inhibitor - Merck/International Partnership for Microbicides

Drug Profile

Research programme: gp41 fusion inhibitor - Merck/International Partnership for Microbicides

Alternative Names: HIV envelope protein gp41 fusion inhibitor - Merck/IPM; L'644; L-644

Latest Information Update: 29 Aug 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Env gene products; Peptide fragments; Peptides; Viral fusion proteins
  • Mechanism of Action HIV fusion inhibitors; Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 29 Aug 2011 Preclinical development is ongoing in USA
  • 11 Mar 2008 International Partnership for Microbicides acquires royalty-free license to L '644 from Merck & Co.
  • 11 Mar 2008 Preclinical trials in HIV infections in USA (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top